PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

NICE recommends cenobamate for treatment of adult epilepsy patients in UK

NICE has issued a positive recommendation for Arvelle Therapeutics’ cenobamate (Ontozry), for the treatment of focal-onset seizures in adults with uncontrolled epilepsy in England and Wales.

The Final Appraisal Document (FAD) recommends cenobamate as an option for treating focal onset seizures with or without secondary generalised seizures, in adults with drug-resistant epilepsy that has not been adequately controlled with at least two other antiseizure medicines. Cenobamate is recommended as an add-on treatment, after at least one other add-on treatment has not controlled seizures.

The recommendation is supported by data from key trials C017 and C021, involving 1,784 patients. The pivotal trial (study C017) demonstrated a reduction in focal (partial)-onset seizures frequency, with patients receiving 100mg, 200mg, and 400mg of cenobamate versus placebo. Adverse reactions reported in the study included dizziness, headache, fatigue, and diplopia.

Cenobamate, discovered and developed by SK Biopharmaceuticals and SK life science, was approved by the FDA for the treatment of focal-onset seizures in adults in 2019 and is commercially available in the US under the brand name XCOPRI (cenobamate tablets) CV.

Epilepsy affects over 600,000 people in the UK, which is approximately one in every 100 people. In some cases, epileptic seizures can be fatal, and an estimated 1,000 people die in the UK every year because of the condition.

Stuart Mulheron, General Manager UK & Ireland, Angelini Pharma, commented: “Angelini Pharma is committed to improving seizure control for people living with epilepsy. Today’s positive recommendation for cenobamate by NICE is a testament to the strength of key trial data and offers the prospect of better management for people affected by uncontrolled seizures in the UK. The FAD is a significant milestone for cenobamate and takes us closer towards reimbursement in England and Wales.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026